Plasmodium vivax the first-line treatment for "P. falciparum" malaria, it may also be used for P. vivax malaria in combination with primaquine for radical cure. An exception is artesunate plus sulfadoxine-pyrimethamine (AS+SP), which is not effective against P. vivax in many places. Mefloquine is a good alternative and in some countries is more readily available. Atovaquone-proguanil is an effective alternative in patients unable to tolerate chloroquine. Quinine may be used to treat "vivax" malaria but is associated with inferior outcomes. 32–100% of patients will relapse following successful treatment of "P. vivax" infection if a radical cure (eradication of liver stages) is not
Treatment of equine lameness cells may be harvested from other horses ahead of time to have banked for immediate treatment of an injury, but there is some concerns of graft-vs-host disease. Stem cells have been used to treat a variety of injuries in horses. The most research has been performed on stem cells used for treatment of tendon and meniscal injuries. Horses with tendonitis treated with bone marrow derived stem cells had a significantly lower re-injury rate compared to those without treatment. Stem cell treatment in damaged tendons is thought to improve the collagen make-up of the tendon while healing. It has been shown